<DOC>
	<DOCNO>NCT00191711</DOCNO>
	<brief_summary>The purpose study determine whether neoadjuvant intravesical Gemcitabine enough active patient solitary , low risk superficial bladder cancer.After diagnostic urethrocystoscopy bladder sonography , patient receive intravesical gemcitabine week 6 week . Two week finish antiblastic therapy , patient submit new cystoscopy , TUR cold biopsy site initial lesion .</brief_summary>
	<brief_title>Intravesical Gemcitabine Instillation Followed Transurethral Resection Treatment Patients With Superficial Bladder Cancer Low Risk .</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Primary solitary bladder tumour exceed 2 cm diameter sonography and/or cystoscopy , judge investigator muscle infiltrate low risk Urinary cytology negative severe dysplasia ( G3 ) . ECOG performance status 01 Absence anticoagulant therapy acetylsalicylic acid chronic therapy Absence present past neoplasia except heal skin basalioma Tumours infiltrative pattern cystoscopy Transitional carcinoma upper urinary tract prostatic urethra . Any previous concomitant malignancy superficial bladder cancer exception cutaneous basalioma and/or cancer cervix , adequately treat .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>